North Asian International Research Journal of Pharmaceutical & Medical Sciences

IRJIF: 5.012

ISSN: 2456-8287 Vol. 7, Issue-4 April-2023

Index Copernicus Value: 64.15 Fulfill MCI Criteria Indian Citation Index

NAIRJC A Peer Reviewed Refereed Journal

DOI: 10.5859/2456-8287/nairjc_6.9.30

UNDERSTANDING JAUNDICE: CAUSES, PATHOPHYSIOLOGY, AND CLINICAL EVALUATION

[1]ANEEBA ZAINAB & [2]TURAB HYDER

[1,2]*Multi Organ Transplant Canter Bengaluru, Karnataka.*

ABSTRACT

Jaundice, characterized by yellowish discoloration of the skin, sclera, and mucous membranes, is a common medical condition with various underlying causes. Bilirubin accumulation in the body due to its incomplete excretion or overproduction is the main pathophysiological mechanism leading to jaundice. The causes of jaundice can be pre-hepatic, hepatic, or post-hepatic, and include conditions such as hemolysis, viral hepatitis, alcoholic liver disease, choledocholithiasis, cholangiocarcinoma, and pancreatic cancer. The clinical manifestations of jaundice may vary depending on the underlying cause and severity of the condition, but often include yellowing of the skin and sclera, dark urine, and pale stools. The evaluation of jaundice includes a thorough medical history and physical examination, as well as laboratory tests and imaging studies. Treatment depends on the underlying cause of the condition and may include medications, lifestyle modifications, or surgical intervention.

KEYWORDS: ***jaundice, bilirubin, liver disease, hepatitis, hemolysis, choledocholithiasis, cholangiocarcinoma, pancreatic cancer.***

I. INTRODUCTION

A. Definition and overview of jaundice Jaundice, also known as icterus, is a medical condition characterized by yellowish discoloration of the skin, sclera (white part of the eye), and mucous membranes due to the accumulation of bilirubin in the body. Bilirubin is a yellowish pigment formed from the breakdown of hemoglobin in red blood cells. B. Historical background of jaundice the term "jaundice" originates from the French word "jaune," meaning

yellow. The earliest known description of jaundice dates back to the 4th century BCE by Hippocrates, who noted the yellow discoloration of the skin in patients with liver disease. Over time, the understanding of the pathophysiology and causes of jaundice has evolved through the works of many prominent physicians and scientists. C. Epidemiology of jaundice Jaundice is a common medical condition, affecting people of all ages and ethnicities worldwide. The incidence and prevalence of jaundice vary depending on the underlying cause and geographic location. In developed countries, the most common causes of jaundice are viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease, while in developing countries, hemolysis and infectious causes predominate.

II. CAUSES OF JAUNDICE

A. Pre-hepatic causes

Hemolysis: Hemolysis is the destruction of red blood cells, resulting in the release of hemoglobin and bilirubin into the bloodstream. This can be caused by genetic disorders, such as sickle cell disease, or acquired conditions, such as autoimmune hemolytic anemia.

Ineffective erythropoiesis: Ineffective erythropoiesis is the abnormal production of red blood cells that are prematurely destroyed in the bone marrow, leading to increased bilirubin levels. This can be caused by conditions such as thalassemia. B. Hepatic causes

Viral hepatitis: Viral hepatitis is a viral infection that can cause inflammation of the liver and lead to jaundice. Hepatitis A, B, and C are the most common causes of viral hepatitis.

Alcoholic liver disease: Alcoholic liver disease is a chronic condition caused by excessive alcohol consumption, leading to inflammation and scarring of the liver and eventually jaundice.

Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease is a condition characterized by the accumulation of fat in the liver, which can progress to inflammation, scarring, and jaundice. C. Post-hepatic causes

Choledocholithiasis: Choledocholithiasis is the presence of gallstones in the common bile duct, obstructing the flow of bile from the liver to the small intestine, leading to jaundice.

Cholangiocarcinoma: Cholangiocarcinoma is a rare cancer of the bile ducts that can obstruct the flow of bile, leading to jaundice.

Pancreatic cancer: Pancreatic cancer can obstruct the common bile duct, leading to jaundice.

III. PATHOPHYSIOLOGY OF JAUNDICE

A. Bilirubin metabolism

Bilirubin is a yellowish pigment that is formed from the breakdown of heme, a component of hemoglobin found in red blood cells. Bilirubin is transported to the liver, where it is conjugated with glucuronic acid to form water-soluble bilirubin glucuronide, which can be excreted in bile. Bile flows from the liver into the duodenum, where it aids in the digestion and absorption of fats.

B. Consequences of excess bilirubin

Excess bilirubin in the blood can lead to jaundice, a yellowish discoloration of the skin and sclera. Other consequences of excess bilirubin may include:

Pruritus (itching)

Dark urine

Pale stools

Hepatic encephalopathy (a neuropsychiatric disorder resulting from liver dysfunction)

Coagulopathy (impaired blood clotting)

Malnutrition

C. Clinical manifestations

The clinical manifestations of jaundice may vary depending on the underlying cause and severity of the condition. The most common symptoms include yellowing of the skin and sclera, dark urine, and pale stools. Patients with jaundice may also experience fatigue, weakness, and abdominal pain. In cases where the underlying cause of jaundice is liver disease, additional symptoms such as ascites (fluid accumulation in the abdomen), hepatic encephalopathy, and coagulopathy may be present.

Patients with obstructive jaundice (due to blockage of the bile ducts) may experience additional symptoms such as pruritus (itching), fever, and abdominal distention. In some cases, jaundice may be an incidental finding on laboratory tests, with no accompanying symptoms.

IV. CLINICAL EVALUATION OF JAUNDICE

A. History and physical examination

A thorough history and physical examination are crucial in the evaluation of jaundice. The physician should take a detailed medical history, including the onset, duration, and progression of jaundice, as well as any associated symptoms. The patient's history should also include a review of medications, alcohol and drug use, and exposure to toxins.

During the physical examination, the physician should examine the patient for signs of jaundice, including yellowing of the skin and sclera. The abdomen should be palpated for tenderness, hepatomegaly (enlarged liver), or splenomegaly (enlarged spleen). Other signs that may be present in patients with liver disease include ascites, spider angiomas (small spider-like blood vessels on the skin), and encephalopathy.

B. Laboratory evaluation

The laboratory evaluation of jaundice typically includes liver function tests (LFTs), serum bilirubin, imaging studies, and in some cases, liver biopsy.

Liver function tests (LFTs): LFTs are a group of blood tests that evaluate the function of the liver. These tests typically include measurement of serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT). Abnormal levels of these enzymes may suggest liver injury or disease.

Serum bilirubin: Measurement of serum bilirubin levels is an important part of the evaluation of jaundice. Elevated levels of serum bilirubin are indicative of impaired bilirubin metabolism, and can help distinguish between pre-hepatic, hepatic, and post-hepatic causes of jaundice.

Imaging studies: Imaging studies, such as abdominal ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI), may be used to evaluate the liver, bile ducts, and pancreas. These studies can help identify structural abnormalities or blockages that may be causing jaundice.

Liver biopsy: In some cases, a liver biopsy may be necessary to establish the underlying cause of jaundice. During a liver biopsy, a small piece of liver tissue is removed and examined under a microscope for signs of inflammation, fibrosis, or other abnormalities.

In addition to these tests, other laboratory studies may be ordered based on the suspected underlying cause of jaundice, such as serologic testing for viral hepatitis, or a complete blood count (CBC) to evaluate for anemia or other blood disorders.

V. MANAGEMENT OF JAUNDICE

A. Treatment of underlying cause:

Hemolysis: Treatment of hemolysis involves addressing the underlying cause, such as a blood disorder or infection, and providing supportive care. In severe cases, blood transfusions may be necessary to replace the lost red blood cells.

Viral hepatitis: Treatment of viral hepatitis depends on the specific virus causing the infection. Antiviral medications are available for the treatment of hepatitis B and C, while hepatitis A usually resolves on its own. Treatment may also involve supportive care, such as rest, hydration, and pain relief.

Alcoholic liver disease: The mainstay of treatment for alcoholic liver disease is abstinence from alcohol. Other treatments may include medications to manage symptoms and complications, as well as nutritional support to prevent malnutrition.

Non-alcoholic fatty liver disease: Treatment of non-alcoholic fatty liver disease involves lifestyle modifications, such as weight loss through diet and exercise, and management of underlying conditions such as diabetes and high blood pressure.

Choledocholithiasis: Treatment of choledocholithiasis typically involves removing the bile duct stones using endoscopic retrograde cholangiopancreatography (ERCP) or surgery.

Cholangiocarcinoma and pancreatic cancer: Treatment of these cancers may involve surgery, chemotherapy, radiation therapy, or a combination of these treatments.

B. Symptomatic management:

Pruritus: Treatment of pruritus may involve medications such as cholestyramine or ursodeoxycholic acid, as well as skin care measures to prevent scratching and further skin damage.

Malnutrition: Nutritional support may be necessary in individuals with jaundice to prevent malnutrition. This may involve dietary changes, nutritional supplements, or enteral or parenteral feeding.

Coagulopathy: Treatment of coagulopathy may involve administration of blood products such as fresh frozen plasma or prothrombin complex concentrate, as well as treatment of the underlying cause.

Encephalopathy: Treatment of encephalopathy may involve medications to reduce ammonia levels in the blood, as well as management of the underlying cause.

C. Complications and their management:

Ascites: Treatment of ascites may involve dietary sodium restriction, diuretics, and paracentesis to drain excess fluid.

Variceal bleeding: Treatment of variceal bleeding may involve endoscopic band ligation or sclerotherapy, as well as medication to reduce portal hypertension.

Hepatic encephalopathy: Treatment of hepatic encephalopathy may involve medications to reduce ammonia levels in the blood, as well as management of the underlying cause.

Liver failure: Treatment of liver failure may involve supportive care, such as fluid and electrolyte management, as well as treatment of the underlying cause. In severe cases, liver transplantation may be necessary.

VI. PREVENTION OF JAUNDICE

A. Prevention of viral hepatitis:

Vaccination: Vaccines are available for hepatitis A and B, and it is recommended to get vaccinated to protect against these infections.

Safe sex practices: Practicing safe sex can prevent the transmission of hepatitis B and C.

Avoid sharing needles: Avoiding sharing needles, razors, and other personal items can reduce the risk of contracting hepatitis B and C.

Screening of blood products: Screening of blood products before transfusion can prevent the transmission of hepatitis B and C.

Precautions for healthcare workers: Healthcare workers should follow strict infection control measures to avoid contracting and transmitting hepatitis B and C infections.

B. Lifestyle modifications to prevent liver damage:

Avoid alcohol consumption or limit it to moderate levels.

Maintain a healthy weight through a balanced diet and regular exercise.

Avoid the use of recreational drugs and limit the use of prescription medications as directed by a healthcare provider.

Practice safe sex to avoid contracting sexually transmitted infections, which can lead to liver damage.

Avoid exposure to toxins, such as chemicals and pollutants, that can cause liver damage.

C. Prevention of other underlying causes:

Management of diabetes and high blood pressure to prevent the development of non-alcoholic fatty liver disease.

Regular monitoring of liver function in individuals with a history of liver disease, including hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease.

Early detection and management of gallstones to prevent complications such as cholecystitis and cholangitis.

Quitting smoking, as it is a risk factor for many underlying causes of liver disease.

VII. CONCLUSION

A. Summary of key points:

Jaundice is a common medical condition characterized by the yellowing of the skin and the whites of the eyes due to excess bilirubin in the blood. It can result from a variety of underlying causes, including pre-hepatic, hepatic, and post-hepatic factors.

Pre-hepatic causes of jaundice include hemolysis and ineffective erythropoiesis, while hepatic causes include viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease. Post-hepatic causes include choledocholithiasis, cholangiocarcinoma, and pancreatic cancer.

The pathophysiology of jaundice involves the breakdown of heme from red blood cells, which is then converted to bilirubin in the liver. Excess bilirubin can lead to a variety of clinical manifestations, including yellowing of the skin and eyes, dark urine, and pale stools.

Clinical evaluation of jaundice involves a thorough history and physical examination, as well as laboratory evaluation, including liver function tests, serum bilirubin levels, imaging studies, and liver biopsy if necessary.

Management of jaundice involves treating the underlying cause, such as hemolysis, viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, choledocholithiasis, cholangiocarcinoma, or pancreatic cancer. Symptomatic management includes addressing complications such as pruritus, malnutrition, coagulopathy, and encephalopathy.

Prevention of jaundice involves measures to prevent viral hepatitis, lifestyle modifications to prevent liver damage, and prevention of other underlying causes.

B. Implications for clinical practice and future research:

Effective management of jaundice requires prompt identification and treatment of the underlying cause, as well as careful monitoring for complications. Future research should focus on developing more effective prevention strategies and treatments for jaundice, particularly in populations at high risk for liver disease. Clinicians should also focus on patient education and counseling to promote healthy lifestyle habits and reduce the risk of liver damage.

REFERENCES

[1]. Gholami N, Asadi A, Hosseini SM, Ebrahimi S. Jaundice: a review of the epidemiology, pathophysiology, diagnosis, and management of neonatal and adult jaundice. Clin Exp Hepatol. 2019;5(2):93-105. doi:10.5114/ceh.2019.85217

[2]. Behairy BE, Sabry SM, Zalata KR. Understanding the causes of neonatal jaundice. J Pediatr Neonatal Care. 2015;2(2):00052. doi:10.15406/jpnc.2015.02.00052

[3]. Moyer V, Freese DK, Whitington PF, et al. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2004;39(2):115-128. doi:10.1097/00005176-200408000-00001

[4]. Ostrow JD. Jaundice. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Elsevier; 2020:1515-1518.e1.

[5]. Pratt DS, Kaplan MM. Evaluation of the patient with jaundice or abnormal liver tests. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 11th ed. Elsevier; 2021:1322-1336.